On the public citation graph
Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance
0 signed · 99 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/gps.1133openalex-snapshot
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trials
inferredcites →https://doi.org/10.1016/j.clinthera.2010.06.019openalex-snapshot
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
inferredcites →https://doi.org/10.1016/j.jalz.2014.05.613openalex-snapshot
P1‐371: EFFICACY AND TOLERABILITY OF DONEPEZIL 23MG/D VERSUS DONEPEZIL 10MG/D IN PATIENTS WITH MODERATE TO SEVERE AD IN AN ASIAN POPULATION: STUDY 326 SUBANALYSIS
inferredcites →https://doi.org/10.1016/s0140-6736(06)68350-5openalex-snapshot
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study
inferredcites →https://doi.org/10.1046/j.1532-5415.2001.t01-1-49266.xopenalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting
inferredcites →https://doi.org/10.1056/nejmoa1106668openalex-snapshot
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
inferredcites →https://doi.org/10.1111/ane.12195openalex-snapshot
Galantamine treatment in outpatients with mild Alzheimer's disease
inferredcites →https://doi.org/10.1111/cns.12076openalex-snapshot
High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines
inferredcites →https://doi.org/10.1159/000091790openalex-snapshot
3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy
inferredcites →https://doi.org/10.1159/000122961openalex-snapshot
Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial
inferredcites →https://doi.org/10.1159/000203887openalex-snapshot
Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer’s Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
inferredcites →https://doi.org/10.1159/000338236openalex-snapshot
Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
inferredcites →https://doi.org/10.1159/000345279openalex-snapshot
Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
inferredcites →https://doi.org/10.1185/03007990903236731openalex-snapshot
Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials
inferredcites →https://doi.org/10.1186/1471-2377-11-57openalex-snapshot
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
inferredcites →https://doi.org/10.1186/1756-0500-5-283openalex-snapshot
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
inferredcites →https://doi.org/10.1186/alzrt166openalex-snapshot
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
inferredcites →https://doi.org/10.1212/01.wnl.0000134664.80320.92openalex-snapshot
Efficacy of donepezil in mild cognitive impairment
inferredcites →https://doi.org/10.1212/01.wnl.0000266627.96040.5aopenalex-snapshot
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
inferredcites →https://doi.org/10.1212/01.wnl.0000344650.95823.03openalex-snapshot
Donepezil treatment of patients with MCI
inferredcites →https://doi.org/10.2147/cia.s39959openalex-snapshot
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors
inferredcites →https://doi.org/10.2165/00002512-200825020-00008openalex-snapshot
Safety and Tolerability of Donepezil at Doses up to 20 mg/day
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4645306openalex-extracted
Action Mechanisms of Donepezil in Cardiac and Vascular Aspects: A Review
inferred← citeshttps://doi.org/10.1002/14651858.cd001190.pub3openalex-snapshot
Donepezil for dementia due to Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/9783527813421.ch10openalex-snapshot
Therapeutic Agents for Neurodegenerative Disorders
inferred← citeshttps://doi.org/10.1002/adsc.201801457openalex-snapshot
Direct Reductive Amination of Carbonyl Compounds with H2 Using Heterogeneous Catalysts in Continuous Flow as an Alternative to N‐Alkylation with Alkyl Halides
inferred← citeshttps://doi.org/10.1002/cbdv.202100361openalex-snapshot
Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment
inferred← citeshttps://doi.org/10.1002/fsn3.2102openalex-snapshot
The seed oil of Paeonia ludlowii ameliorates Aβ25‐35‐induced Alzheimer's disease in rats
inferred← citeshttps://doi.org/10.1002/gps.6157openalex-snapshot
Projected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic
inferred← citeshttps://doi.org/10.1002/slct.202003573openalex-snapshot
Design and Development of Cholinesterase Dual Inhibitors towards Alzheimer's Disease Treatment: A Focus on Recent Contributions from Computational and Theoretical Perspective
inferred← citeshttps://doi.org/10.1002/trc2.12168openalex-snapshot
Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative
inferred← citeshttps://doi.org/10.1007/s11011-021-00777-6openalex-snapshot
Mesenchymal stem cell therapies for Alzheimer’s disease: preclinical studies
inferred← citeshttps://doi.org/10.1007/s11030-022-10377-wopenalex-snapshot
Pharmacophore mapping of the crucial mediators of acetylcholinesterase and butyrylcholinesterase dual inhibition in Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/b978-0-443-15702-8.00027-0openalex-snapshot
Pharmacotherapy of Alzheimer's disease: A thorny road to success
inferred← citeshttps://doi.org/10.1016/j.addr.2025.115655openalex-snapshot
Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders
inferred← citeshttps://doi.org/10.1016/j.bbrep.2022.101392openalex-snapshot
The effect of combination pretreatment of donepezil and environmental enrichment on memory deficits in amyloid-beta-induced Alzheimer-like rat model
inferred← citeshttps://doi.org/10.1016/j.biopha.2018.11.115openalex-snapshot
The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches
inferred← citeshttps://doi.org/10.1016/j.bmcl.2016.09.072openalex-snapshot
Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.cger.2022.07.008openalex-snapshot
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias
inferred← citeshttps://doi.org/10.1016/j.ejphar.2020.173193openalex-snapshot
Geranylgeranyl acetone prevents glutamate-induced cell death in HT-22 cells by increasing mitochondrial membrane potential
inferred← citeshttps://doi.org/10.1016/j.hermed.2019.100291openalex-snapshot
Nootropic medicinal plants: Therapeutic alternatives for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.ibneur.2022.11.005openalex-snapshot
Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction
inferred← citeshttps://doi.org/10.1016/j.jconrel.2020.02.020openalex-snapshot
Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting
inferred← citeshttps://doi.org/10.1016/j.lfs.2016.11.001openalex-snapshot
Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.snb.2024.136895openalex-snapshot
A strategy of monitoring acetylcholinesterase and screening of natural inhibitors from Uncaria for Alzheimer's disease therapy based on near-infrared fluorescence probe
inferred← citeshttps://doi.org/10.1021/acs.jafc.4c00836openalex-snapshot
Pongamol Alleviates Neuroinflammation and Promotes Autophagy in Alzheimer’s Disease by Regulating the Akt/mTOR Signaling Pathway
inferred← citeshttps://doi.org/10.1021/acschemneuro.8b00450openalex-snapshot
Implications of Successful Symptomatic Treatment in Parkinson’s Disease for Therapeutic Strategies of Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1021/acsnano.3c08823openalex-snapshot
Rational Design of Dual-Functionalized Gd@C82 Nanoparticles to Relieve Neuronal Cytotoxicity in Alzheimer’s Disease via Inhibition of Aβ Aggregation
inferred← citeshttps://doi.org/10.1021/acsomega.0c00057openalex-snapshot
Effects of α-Mangostin Derivatives on the Alzheimer’s Disease Model of Rats and Their Mechanism: A Combination of Experimental Study and Computational Systems Pharmacology Analysis
inferred← citeshttps://doi.org/10.1021/acsomega.6c07555openalex-snapshot
Rapid HPLC-Based ADME Profiling of Novel Donepezil and Rivastigmine Analogues for Potential Application in Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1038/s41746-021-00452-1openalex-snapshot
Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1055/a-2076-7939openalex-snapshot
Phytopharmaceuticals and Herbal Approaches to Target Neurodegenerative Disorders
inferred← citeshttps://doi.org/10.1080/01616412.2018.1480921openalex-snapshot
Silencing of LncRNA BDNF-AS attenuates Aβ25-35-induced neurotoxicity in PC12 cells by suppressing cell apoptosis and oxidative stress
inferred← citeshttps://doi.org/10.1080/07391102.2020.1826129openalex-snapshot
Multi-target approach for Alzheimer’s disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4- N -phenylaminoquinoline derivative reveal promising potentials
inferred← citeshttps://doi.org/10.1080/14740338.2022.2027905openalex-snapshot
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/oso/9780190634230.003.0019openalex-snapshot
Management of Mild Cognitive Impairment
inferred← citeshttps://doi.org/10.1097/wnr.0000000000001659openalex-snapshot
Effects of donepezil on the amplitude of low-frequency fluctuations in the brain of patients with Alzheimer’s disease: evidence from resting-state functional magnetic resonance imaging
inferred← citeshttps://doi.org/10.1124/pharmrev.121.000524openalex-snapshot
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance
inferred← citeshttps://doi.org/10.1146/annurev-pharmtox-061020-050936openalex-snapshot
Cholinergic Capsules and Academic Admonitions
inferred← citeshttps://doi.org/10.1159/000518470openalex-snapshot
Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer’s Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial
inferred← citeshttps://doi.org/10.1177/0269881120944155openalex-snapshot
An acetylcholinesterase inhibitor, donepezil, increases anxiety and cortisol levels in adult zebrafish
inferred← citeshttps://doi.org/10.1177/25424823251356233openalex-snapshot
Healthcare related costs associated with donepezil use in patients with very mild dementia due to Alzheimer's disease: A retrospective observational study
inferred← citeshttps://doi.org/10.1186/s12885-022-09806-8openalex-snapshot
Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial
inferred← citeshttps://doi.org/10.1186/s13195-018-0457-9openalex-snapshot
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
inferred← citeshttps://doi.org/10.1186/s13195-019-0492-1openalex-snapshot
Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
inferred← citeshttps://doi.org/10.12659/msm.896327openalex-snapshot
Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease
inferred← citeshttps://doi.org/10.12968/hmed.2024.1037openalex-snapshot
Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1590/s2175-97902024e23618openalex-snapshot
Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches
inferred← citeshttps://doi.org/10.17116/jnevro202312312169openalex-snapshot
Russian experience in using a combination of fixed doses of donepezil and memantine in the treatment of Alzheimer’s disease as an observational non-interventional multicenter program
inferred← citeshttps://doi.org/10.18632/aging.202619openalex-snapshot
Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease
inferred← citeshttps://doi.org/10.18632/oncotarget.13060openalex-snapshot
Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1139026/v1openalex-snapshot
Combination Therapy of Donepezil and Environmental Enrichment on Memory Deficits in Amyloid-Beta-Induced Alzheimer's Disease Rats
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2249735/v1openalex-snapshot
Acetylcholinesterase (AchE) receptor-based In-Silico drug discovery for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.2174/0929867325666180517094023openalex-snapshot
A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer’s Disease
inferred← citeshttps://doi.org/10.2174/0929867331666230703145043openalex-snapshot
Natural Plant Materials as a Source of Neuroprotective Peptides
inferred← citeshttps://doi.org/10.2217/nmt-2016-0005openalex-snapshot
Nondopaminergic Treatments for Parkinson’s Disease: Current and Future Prospects
inferred← citeshttps://doi.org/10.24198/ijbp.v2i2.40462openalex-snapshot
Studi In Silico Senyawa dalam Daun Sirih (Piper betle L.) sebagai Inhibitor Enzim Asetilkolinesterase (AChE) pada Penyakit Alzheimer
inferred← citeshttps://doi.org/10.24198/ijbp.v3i2.47498openalex-snapshot
Studi In Silico Senyawa Bioaktif Buah Lada Hitam (Piper nigrum L.) sebagai Inhibitor Enzim Asetilkolinesterase (AChE) pada Penyakit Alzheimer
inferred← citeshttps://doi.org/10.26599/jnr.2019.9040026openalex-snapshot
Traditional Chinese medicine-based neurorestorative therapy for Alzheimer’s and Parkinson’s disease
inferred← citeshttps://doi.org/10.3233/jad-210234openalex-snapshot
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
inferred← citeshttps://doi.org/10.3233/jin-170020openalex-snapshot
Effects of donepezil on liver and kidney functions for the treatment of Alzheimer’s disease
inferred← citeshttps://doi.org/10.3389/fimmu.2021.660342openalex-snapshot
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
inferred← citeshttps://doi.org/10.3389/fneur.2019.01266openalex-snapshot
A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease
inferred← citeshttps://doi.org/10.3389/fphar.2020.00261openalex-snapshot
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
inferred← citeshttps://doi.org/10.3390/antiox14121509openalex-snapshot
Antiglycative Properties of Anti-Dementia Drugs—In Vitro, In Silico Studies and a Systematic Literature Review
inferred← citeshttps://doi.org/10.3390/brainsci8090177openalex-snapshot
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
inferred← citeshttps://doi.org/10.3390/ijms22042033openalex-snapshot
The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer’s Disease Pathogenesis
inferred← citeshttps://doi.org/10.3390/ijms22063120openalex-snapshot
Design and Synthesis of Ranitidine Analogs as Multi-Target Directed Ligands for the Treatment of Alzheimer’s Disease
inferred← citeshttps://doi.org/10.3390/ijms24108991openalex-snapshot
Effects of Donepezil on the Musculoskeletal System in Female Rats
inferred← citeshttps://doi.org/10.3390/membranes16100315openalex-snapshot
Biomimetic ADME Profiling of Multifunctional Biphenylalkoxyamine-Related Histamine H3 Receptor Ligands with Anti-Alzheimer Potential
inferred← citeshttps://doi.org/10.3390/molecules22081254openalex-snapshot
Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer’s Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches
inferred← citeshttps://doi.org/10.3390/nu9020105openalex-snapshot
Lychee Seed Saponins Improve Cognitive Function and Prevent Neuronal Injury via Inhibiting Neuronal Apoptosis in a Rat Model of Alzheimer’s Disease
inferred← citeshttps://doi.org/10.34024/rnc.2021.v29.12413openalex-snapshot
Pharmacological drug strategies in Alzheimer's Disease
inferred← citeshttps://doi.org/10.3892/ijmm.2017.3245openalex-snapshot
Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairment
inferred← citeshttps://doi.org/10.4103/1673-5374.259604openalex-snapshot
Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer’s disease
inferred← citeshttps://doi.org/10.53841/bpsfpop.2019.1.148.26openalex-snapshot
Pharmacological interventions in dementia
inferred← citeshttps://doi.org/10.5772/intechopen.94950openalex-snapshot
Neurodegeneration: Diagnosis, Prevention, and Therapy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.